9/30/2013 6:51:37 AM
Protalex, Inc. (OTCBB:PRTX), a clinical-stage biopharmaceutical company, today announced that two posters relating to PRTX-100, the Company’s investigational drug, were accepted for presentation at the 2013 American College of Rheumatology ARHP Annual Meeting, to be held at the San Diego Convention Center from October 25 – 30, 2013. PRTX-100 is a highly purified form of Staphylococcal Protein A, an immunodulatory bacterial protein. The complete abstracts for the posters can be accessed in the Science section of the Company’s website at www.protalex.com.
Help employers find you! Check out all the jobs and post your resume.
comments powered by